Marshall Wace
KROS icon

Marshall Wace’s Keros Therapeutics KROS Stock Holding History

Marshall Wace’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$370K Buy
+34,600
New +$385K ﹤0.01% 2635
2024
Q4 		– Sell
-43,500
Closed -$2.53M – 2805
2024
Q3 		$2.53M Buy
43,500
+21,123
+94% +$1.04M ﹤0.01% 1282
2024
Q2 		$1.02M Sell
22,377
-250,594
-92% -$13.5M ﹤0.01% 1679
2024
Q1 		$18.1M Buy
272,971
+223,499
+452% +$13.3M 0.03% 544
2023
Q4 		$1.97M Buy
+49,472
New +$1.55M ﹤0.01% 1229
2023
Q3 		– Sell
-62,650
Closed -$2.52M – 2465
2023
Q2 		$2.52M Sell
62,650
-53,870
-46% -$2.36M ﹤0.01% 1291
2023
Q1 		$4.98M Buy
116,520
+110,120
+1,721% +$5.56M 0.01% 1003
2022
Q4 		$307K Buy
+6,400
New +$299K ﹤0.01% 2560
2022
Q3 		– Sell
-52,934
Closed -$1.46M – 3582
2022
Q2 		$1.46M Buy
52,934
+45,466
+609% +$1.99M ﹤0.01% 2219
2022
Q1 		$406K Buy
7,468
+1,741
+30% +$89.4K ﹤0.01% 2863
2021
Q4 		$335K Sell
5,727
-43,909
-88% -$2.19M ﹤0.01% 2987
2021
Q3 		$1.96M Buy
49,636
+37,581
+312% +$1.34M 0.01% 1566
2021
Q2 		$512K Buy
12,055
+6,178
+105% +$335K ﹤0.01% 2113
2021
Q1 		$362K Sell
5,877
-11,615
-66% -$736K ﹤0.01% 2063
2020
Q4 		$1.23M Buy
+17,492
New +$1.1M 0.01% 1131

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Marshall Wace's KROS Position: Q2 2026 in Review

Marshall Wace opened a new position in Keros Therapeutics (KROS) in Q2 2026: 34,600 shares worth $370K. The stake represents ﹤0.01% of the portfolio and ranks #2635 among its holdings. This is a return to the name: Marshall Wace previously reported a position in KROS as recently as Q3 2024.

Marshall Wace first reported a position in KROS in Q4 2020 and has held it in 15 quarters since. The position peaked at $18.1M in Q1 2024. 133 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Marshall Wace held 34,600 shares of Keros Therapeutics worth $370K as of Q2 2026.
  • Keros Therapeutics was a new Marshall Wace position in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2635 holding.
  • Marshall Wace first reported a position in Keros Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • Marshall Wace's Keros Therapeutics position peaked at $18.1M in Q1 2024.
  • 133 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.